

## Supplementary material 6. Post-assessment insights

Table S6.1. Feedback collected from the group of evaluators and one of the DM, regarding the study conducted to assist IPO Lisboa in the assessment of different genomic testing strategies.

Question	Topics taken from the answers of the participants
Was this <b>study relevant</b> for IPO?	<ul style="list-style-type: none"> <li>• Yes, the study was relevant, especially considering the everchanging landscape of genetic diseases and constant turnover of genomic technologies.</li> </ul>
Was the <b>objective clear</b> from the beginning?	<ul style="list-style-type: none"> <li>• Some aspects of the study were not entirely clear from the beginning, mostly due to some unfamiliar concepts and tools which were used, and the different points of view from which the analysis could be conducted;</li> <li>• The role of the facilitator was crucial in the whole process, working as a bridge between the clinical and the technical fields, and reaching out to different stakeholders.</li> </ul>
Was the applied <b>multi-methodology adequate</b> for this study?	<ul style="list-style-type: none"> <li>• Yes, mostly because it was carefully personalised according to the needs of the institution;</li> <li>• Regarding the value model, the online survey was considered to be a very useful and simple method to collect the opinions of several stakeholders. However, more people should have been involved in order to avoid bias and obtain more consensual results;</li> <li>• Regarding the cost model, the Monte Carlo simulation was a valuable tool for encompassing the uncertainty of all variables;</li> <li>• Lastly, it would have been important to hold an initial meeting with all the stakeholders involved in the project, which was not possible due to logistical constraints.</li> </ul>
Were the <b>results relevant</b> for IPO?	<ul style="list-style-type: none"> <li>• Yes, the obtained results provide a good foundation for IPO to better assess and discuss different genomic testing strategies available in the market.</li> </ul>
What could be done as <b>future work</b> ?	<ul style="list-style-type: none"> <li>• Involving more stakeholders in the study will better reflect the different perspectives which can be considered in the decision-making process;</li> <li>• Finally, it would also be interesting to apply a similar method for other pathologies within IPO.</li> </ul>